Stocks of the Hour: Origin Energy, Sunstone Metals, Chimeric Therapeutics
Stocks of the Hour: Origin Energy, Sunstone Metals, Chimeric Therapeutics
Chimeric Therapeutics (ASX:CHM) announced that the 1st patient has been dosed in the Phase 1B CHM 1101 in their brain cancer clinical trial. The Phase 1B clinical trial builds off the recent positive Phase 1A clinical data. Shares are trading flat at 2.9 cents.To register for Friday's webinar click here.
要註冊參加週五的網絡研討會，請單擊此處。
Origin Energy (ASX:ORG) announced that the Brookfield-led consortium of investors and EIG has significantly increased the cash consideration to best and final proposal of $9.53 per share. In response, Origin Chairman Scott Perkins said, "the revised consideration is now above the top end of the Independent Expert's 30 June 2023 valuation range, allowing all shareholders to receive a certain cash value for their Origin shares." Shares are trading 1.54 per cent lower at $8.93.
Origin Energy (ASX: ORG) 宣佈，布魯克菲爾德領導的投資者財團和EIG已將現金對價大幅提高至每股9.53美元的最佳和最終提案。對此，Origin董事長斯科特·珀金斯表示：“修訂後的對價目前高於獨立專家2023年6月30日估值區間的最高水平，允許所有股東從Origin股票中獲得一定的現金價值。”股價下跌1.54％，至8.93美元。
Sunstone Metals (ASX:STM) announced that the Limon gold-silver discovery, within the Bramaderos Project, is continuing to grow, with more mineralisation identified surrounding the Central Shoot and up to 1km away. In response, Sunstone Managing Director Malcolm Norris said, "These results open up more new areas for drilling and enlarge our target zone." Shares are trading flat at 1.7 cents.
Sunstone Metals (ASX: STM) 宣佈，在布拉馬德羅斯項目內發現的利蒙金銀礦產量持續增長，在Central Shoot周圍以及1公里以外發現了更多的礦化區。對此，Sunstone董事總經理馬爾科姆·諾里斯說：“這些結果爲鑽探開闢了更多新的區域，並擴大了我們的目標區域。”股價持平至1.7美分。
Chimeric Therapeutics (ASX:CHM) announced that the 1st patient has been dosed in the Phase 1B CHM 1101 in their brain cancer clinical trial. The Phase 1B clinical trial builds off the recent positive Phase 1A clinical data. Shares are trading flat at 2.9 cents.
Chimeric Therapeutics (ASX: CHM) 宣佈，在腦癌臨床試驗中，第一位患者已進入1B期CHM 1101給藥。1B期臨床試驗建立在最近的陽性1A期臨床數據基礎上。股價持平至2.9美分。
